EXAS Stock Price | EXACT Sciences Corporation P/E, Revenue, EPS, & Forecasts

EXACT Sciences Corporation • EXAS

EXAS current price

$51.74-21.62%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-11.19%

-12.62%

-25.53%

+7.41%

-21.62%

MAX

+90.50%

About EXACT Sciences Corporation

Ticker

EXAS

Trading on

NASDAQ

ISIN

US30063P1057

Industry

Diagnostics & Research

Sector

Healthcare

CEO

Kevin T. Conroy J.D.

Headquarters

5505 Endeavor Lane, Madison, WI, United States, 53719

Employees

6,500

Website

exactsciences.com

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Metrics

BasicAdvanced

Market cap

$9.58B

P/E ratio

EPS

-$1.16

Dividend Yield

0.00%

Beta

1.27

Forward P/E ratio

2,500

EBIDTA

$-11.3M

Ex dividend date

Price & volume

Market cap

$9.58B

Average daily volume

2.1M

90-day return

-25.53%

30-day return

-12.62%

7-day return

-11.19%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

2,500

PEG ratio

-1.07

Trailing P/E

Price to sales

3.56

Price to book

2.98

Earnings

EPS

-$1.16

EPS estimate (current quarter)

-$0.21

EPS estimate (next quarter)

-$0.07

EBITDA

$-11.3M

Revenues (TTM)

$2.69B

Revenues per share (TTM)

$14.70

Technicals

Beta

1.27

52-week High

$79.62

52-week Low

$40.62

50-day moving average

$57.11

200-day moving average

$57.64

Short ratio

6.15

Short %

5.83%

Management effectiveness

ROE (TTM)

6.76%

ROA (TTM)

2.16%

Profit margin

7.95%

Gross profit margin

$1.96B

Operating margin

2.61%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

12.80%

Share stats

Outstanding Shares

185M

Float

184M

Insiders %

1.02%

Institutions %

101.64%

Analyst Insights & forecasts

87% Buy

13% Hold

0% Sell

Based on information from 23 analysts.

Average price target

$72.29

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.27

-$0.46

41.30%

Q4 • 23Beat

-$0.60

-$0.47

27.66%

Q1 • 24Beat

-$0.09

-$0.32

71.88%

Q2 • 24Beat

-$0.21

Q3 • 24Beat

-$0.33

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$699M

$-15.8M

2.26%

Q2 • 24

$709M

$-38.2M

5.40%

Q3 • 24

1.34%

141.88%

138.67%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$6.67B

$3.48B

52.16%

Q2 • 24

$6.75B

$3.54B

52.43%

Q3 • 24

1.13%

1.64%

0.51%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$107M

$-147M

$225M

$71.2M

Q2 • 24

$139M

$-81.7M

$-0.2M

$113M

Q3 • 24

29.57%

44.46%

100.10%

58.09%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Greed

+1.5

0.50

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a EXACT Sciences Corporation share?

EXACT Sciences Corporation shares are currently traded for $51.74 per share.

How many shares does EXACT Sciences Corporation have?

EXACT Sciences Corporation currently has 185M shares.

Does EXACT Sciences Corporation pay dividends?

No, EXACT Sciences Corporation doesn't pay dividends.

What is EXACT Sciences Corporation 52 week high?

EXACT Sciences Corporation 52 week high is $79.62.

What is EXACT Sciences Corporation 52 week low?

EXACT Sciences Corporation 52 week low is $40.62.

What is the 200-day moving average of EXACT Sciences Corporation?

EXACT Sciences Corporation 200-day moving average is $57.64.

Who is EXACT Sciences Corporation CEO?

The CEO of EXACT Sciences Corporation is Kevin T. Conroy J.D..

How many employees EXACT Sciences Corporation has?

EXACT Sciences Corporation has 6,500 employees.

What is the market cap of EXACT Sciences Corporation?

The market cap of EXACT Sciences Corporation is $9.58B.

What is the P/E of EXACT Sciences Corporation?

The current P/E of EXACT Sciences Corporation is null.

What is the EPS of EXACT Sciences Corporation?

The EPS of EXACT Sciences Corporation is -$1.16.

What is the PEG Ratio of EXACT Sciences Corporation?

The PEG Ration of EXACT Sciences Corporation is -1.07.

What do analysts say about EXACT Sciences Corporation?

According to the analysts EXACT Sciences Corporation is considered a buy.

EXACT Sciences Corporation news

thumb_down_alt

•Negative

Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening. The post Exact Sciences Stock Drops 12% Over Four Days.

Investors Business Daily•16 Jan 2025, 18:20

thumb_up_alt

•Positive

2 Healthcare Stocks to Buy Hand Over Fist in January

Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.

The Motley Fool•16 Jan 2025, 10:22

thumb_up_alt

•Positive

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

On Sunday, Exact Sciences Corp EXAS reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion.

Benzinga•13 Jan 2025, 18:04